The overexpression of fibroblast growth factor receptor 2b (FGFR2b) is tied to tumor progression in several malignancies, such as cholangiocarcinoma, HER2-negative gastric cancer and breast cancer. Lunan Pharmaceutical Group Corp. has developed a novel IgG1 monoclonal antibody against FGFR2b, LNF-2102, for the potential treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) potentially useful for the treatment of cancer. The ADCs comprise an antibody or antigen-binding fragment linked to a cytotoxic drug through a linker.
Alethio Therapeutics (formerly known as Alethiomics Ltd.) has emerged from stealth with two antibody-drug conjugate (ADC) programs for the treatment of myeloproliferative neoplasms (MPNs).
Takeda Pharmaceutical Co. Ltd. agreed to codevelop and commercialize up to three of Innovent Biologics Co. Ltd.’s immuno-oncology (I-O) and antibody-drug conjugate (ADC) candidates with the signing of a $11.4 billion deal, including $1.2 billion paid up front.
Scientists at Wuxi XDC (Shanghai) Co. Ltd. and Wuxi XDC Singapore Pvt Ltd. have divulged antibody-drug conjugates comprising antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer.
Convalife Pharmaceuticals Co. Ltd. has presented data for their bispecific antibody CVL-006, which targets both PD-1 and VEGF-A. CVL-006 blocks both the PD-1-driven immune pathway plus VEGF-A-driven angiogenesis, thus conferring a dual mechanism for superior antitumoral activity.
Researchers at the University of California, Los Angeles (UCLA), have developed a new type of allogeneic immune cell therapy that demonstrated potent antitumor activity against triple-negative breast cancer (TNBC) in preclinical studies.
Adoptive cell therapy represents a major step forward in treating hematological cancers. Among its different approaches, chimeric antigen receptor natural killer (CAR-NK) cells are drawing growing interest.
Takeda Pharmaceutical Co. Ltd. agreed to codevelop and commercialize up to three of Innovent Biologics Co. Ltd.’s immuno-oncology (I-O) and antibody-drug conjugate (ADC) candidates with the signing of a $11.4 billion deal, including $1.2 billion paid up front.
Merck KGaA has prepared and tested new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) linked to exatecan through a β-glucuronidase cleavable linker. They are described as potentially useful for the treatment of ovarian and non-small-cell lung cancer.
RSS
